vs

Side-by-side financial comparison of Assertio Holdings, Inc. (ASRT) and Zedge, Inc. (ZDGE). Click either name above to swap in a different company.

Assertio Holdings, Inc. is the larger business by last-quarter revenue ($13.5M vs $7.6M, roughly 1.8× Zedge, Inc.). On growth, Zedge, Inc. posted the faster year-over-year revenue change (5.8% vs -57.9%). Over the past eight quarters, Zedge, Inc.'s revenue compounded faster (-1.0% CAGR vs -35.4%).

Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As o...

Zedge is a content distribution platform that provides consumers with a way to personalize their mobile devices. It has offices in Trondheim, Vilnius, and New York City.

ASRT vs ZDGE — Head-to-Head

Bigger by revenue
ASRT
ASRT
1.8× larger
ASRT
$13.5M
$7.6M
ZDGE
Growing faster (revenue YoY)
ZDGE
ZDGE
+63.7% gap
ZDGE
5.8%
-57.9%
ASRT
Faster 2-yr revenue CAGR
ZDGE
ZDGE
Annualised
ZDGE
-1.0%
-35.4%
ASRT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ASRT
ASRT
ZDGE
ZDGE
Revenue
$13.5M
$7.6M
Net Profit
$788.0K
Gross Margin
Operating Margin
-86.7%
12.0%
Net Margin
10.4%
Revenue YoY
-57.9%
5.8%
Net Profit YoY
332.4%
EPS (diluted)
$-4.54
$0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASRT
ASRT
ZDGE
ZDGE
Q4 25
$13.5M
$7.6M
Q3 25
$49.5M
$7.5M
Q2 25
$29.2M
$7.8M
Q1 25
$26.5M
$7.0M
Q4 24
$32.2M
$7.2M
Q3 24
$29.2M
$7.6M
Q2 24
$31.1M
$7.7M
Q1 24
$32.4M
$7.8M
Net Profit
ASRT
ASRT
ZDGE
ZDGE
Q4 25
$788.0K
Q3 25
$11.4M
$-559.0K
Q2 25
$-16.4M
$185.0K
Q1 25
$-13.5M
$-1.7M
Q4 24
$-339.0K
Q3 24
$-2.9M
$-39.0K
Q2 24
$-3.7M
$113.0K
Q1 24
$-4.5M
$-9.2M
Operating Margin
ASRT
ASRT
ZDGE
ZDGE
Q4 25
-86.7%
12.0%
Q3 25
23.2%
-9.6%
Q2 25
-27.5%
2.1%
Q1 25
-50.0%
-31.8%
Q4 24
-41.9%
-6.4%
Q3 24
-10.4%
-0.8%
Q2 24
-11.6%
-1.7%
Q1 24
-13.4%
-153.5%
Net Margin
ASRT
ASRT
ZDGE
ZDGE
Q4 25
10.4%
Q3 25
23.1%
-7.5%
Q2 25
-56.0%
2.4%
Q1 25
-51.1%
-24.1%
Q4 24
-4.7%
Q3 24
-10.0%
-0.5%
Q2 24
-11.8%
1.5%
Q1 24
-13.9%
-118.8%
EPS (diluted)
ASRT
ASRT
ZDGE
ZDGE
Q4 25
$-4.54
$0.06
Q3 25
$0.11
$-0.04
Q2 25
$-0.17
$0.01
Q1 25
$-0.14
$-0.12
Q4 24
$-3.28
$-0.02
Q3 24
$-0.03
$0.00
Q2 24
$-0.04
$0.01
Q1 24
$-0.05
$-0.66

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASRT
ASRT
ZDGE
ZDGE
Cash + ST InvestmentsLiquidity on hand
$63.4M
$18.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$94.0M
$25.9M
Total Assets
$267.0M
$36.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASRT
ASRT
ZDGE
ZDGE
Q4 25
$63.4M
$18.5M
Q3 25
$93.4M
$18.6M
Q2 25
$98.2M
$20.4M
Q1 25
$87.3M
$20.1M
Q4 24
$100.1M
$20.2M
Q3 24
$88.6M
$20.0M
Q2 24
$88.4M
$19.9M
Q1 24
$80.7M
$18.1M
Total Debt
ASRT
ASRT
ZDGE
ZDGE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
$38.6M
Stockholders' Equity
ASRT
ASRT
ZDGE
ZDGE
Q4 25
$94.0M
$25.9M
Q3 25
$105.8M
$25.9M
Q2 25
$93.3M
$28.6M
Q1 25
$108.5M
$28.2M
Q4 24
$121.1M
$30.1M
Q3 24
$130.5M
$30.9M
Q2 24
$132.2M
$30.9M
Q1 24
$134.5M
$30.7M
Total Assets
ASRT
ASRT
ZDGE
ZDGE
Q4 25
$267.0M
$36.0M
Q3 25
$319.8M
$35.7M
Q2 25
$273.8M
$37.8M
Q1 25
$286.4M
$37.1M
Q4 24
$284.7M
$38.2M
Q3 24
$276.0M
$38.2M
Q2 24
$279.4M
$38.1M
Q1 24
$282.0M
$37.1M
Debt / Equity
ASRT
ASRT
ZDGE
ZDGE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASRT
ASRT
ZDGE
ZDGE
Operating Cash FlowLast quarter
$-30.0M
$825.0K
Free Cash FlowOCF − Capex
$808.0K
FCF MarginFCF / Revenue
10.6%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
1.05×
TTM Free Cash FlowTrailing 4 quarters
$3.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASRT
ASRT
ZDGE
ZDGE
Q4 25
$-30.0M
$825.0K
Q3 25
$-4.8M
$674.0K
Q2 25
$19.1M
$870.0K
Q1 25
$-12.5M
$708.0K
Q4 24
$11.5M
$1.2M
Q3 24
$-35.0K
$695.0K
Q2 24
$7.4M
$2.3M
Q1 24
$7.5M
$1.6M
Free Cash Flow
ASRT
ASRT
ZDGE
ZDGE
Q4 25
$808.0K
Q3 25
$640.0K
Q2 25
$851.0K
Q1 25
$689.0K
Q4 24
$1.2M
Q3 24
$683.0K
Q2 24
$2.3M
Q1 24
$1.6M
FCF Margin
ASRT
ASRT
ZDGE
ZDGE
Q4 25
10.6%
Q3 25
8.6%
Q2 25
11.0%
Q1 25
9.9%
Q4 24
16.1%
Q3 24
9.0%
Q2 24
30.4%
Q1 24
20.0%
Capex Intensity
ASRT
ASRT
ZDGE
ZDGE
Q4 25
0.2%
Q3 25
0.5%
Q2 25
0.2%
Q1 25
0.3%
Q4 24
0.2%
Q3 24
0.0%
0.2%
Q2 24
0.2%
Q1 24
0.0%
Cash Conversion
ASRT
ASRT
ZDGE
ZDGE
Q4 25
1.05×
Q3 25
-0.42×
Q2 25
4.70×
Q1 25
Q4 24
Q3 24
Q2 24
20.73×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASRT
ASRT

Products$12.8M95%
Other$719.0K5%

ZDGE
ZDGE

Zedge Marketplace$7.1M94%
Other$468.0K6%

Related Comparisons